Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality - PubMed (original) (raw)

Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality

Pegah Golabi et al. Clin Diabetes. 2019 Jan.

Abstract

IN BRIEF Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized and common cause of chronic liver disease worldwide. Although most patients with NAFLD are obese, a smaller group of NAFLD patients are lean. This study explored the long-term outcomes of lean patients with NAFLD in the United States. Compared to lean individuals without NAFLD, lean people with NAFLD were significantly more likely to be older and male and had higher comorbidities (i.e., diabetes, hyperlipidemia, hypertension, metabolic syndrome, chronic kidney disease, and cardiovascular disease). The presence of NAFLD in lean individuals was independently associated with increased risk of all-cause and cardiovascular mortality.

PubMed Disclaimer

Figures

FIGURE 1.

FIGURE 1.

Study flow of the analytical cohort selection from NHANES III. ALD, alcoholic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus.

FIGURE 2.

FIGURE 2.

Adjusted survival curves on Cox proportion hazards model for all-cause mortality among lean individuals, NHANES III (1988–1994). aHR, adjusted HR.

FIGURE 3.

FIGURE 3.

Adjusted survival curves on Cox proportion hazards model for cardiovascular mortality among lean individuals, NHANES III (1988–1994). aHR, adjusted HR.

References

    1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11–20 - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328–357 - PubMed
    1. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123–133 - PMC - PubMed
    1. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016;64:1577–1586 - PubMed
    1. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547–555 - PubMed

LinkOut - more resources